(Q34657961)

3 August 2017

1 reference

title

Surgery and adjunctive chemotherapy for invasive bladder cancer (English)

1 reference

3 August 2017

1 reference

David Quinn

2

0 references

author name string

Derek Raghavan

series ordinal

1

1 reference

3 August 2017

Donald G Skinner

series ordinal

3

1 reference

3 August 2017

John P Stein

series ordinal

4

1 reference

3 August 2017

publication date

1 June 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

11

1 reference

3 August 2017

issue

1-2

1 reference

3 August 2017

page(s)

55-63

1 reference

Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Accumulation of nuclear p53 and tumor progression in bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

p53 and treatment of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Transferrin receptor expression by human bladder transitional cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Treatment of carcinomatous meningitis from transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Pre-emptive (neo-adjuvant) intravenous chemotherapy for invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Neo-adjuvant (Pre-emptive) Cisplatin Therapy in Invasive Transitional Cell Carcinoma of the Bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced Bladder Cancer Overview Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Advanced Bladder Cancer (Stages pT3b, pT4a, pN1 and pN2): Improved Survival after Radical Cystectomy and 3 Adjuvant Cycles of Chemotherapy. Results of a Controlled Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900007-5

7 January 2021

10.1016/S0960-7404(02)00007-5

Identifiers

DOI

1 reference

3 August 2017

1 reference